Atossa Therapeutics, Inc. (ATOS) Financials

ATOS Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 32.3 million 5.5 million
March 31, 2026 37.9 million 7.5 million
Dec. 31, 2025 47.6 million 8.3 million
Sept. 30, 2025 58.0 million 8.2 million

ATOS Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -9.6 million 815000
March 31, 2026 -9.6 million 722000
Dec. 31, 2025 -10.5 million 503000
Sept. 30, 2025 -6.0 million 784000

ATOS Net Income

No data available :(

ATOS Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 26.1 million - -
March 31, 2026 31.7 million - -
Dec. 31, 2025 41.3 million - -
Sept. 30, 2025 51.8 million - -

ATOS Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 8.9 million
March 31, 2026 8.6 million
Dec. 31, 2025 8.6 million
Sept. 30, 2025 8.6 million

ATOS Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 - 4.9 million 3.8 million -
March 31, 2026 - 4.8 million 5.1 million -4000
Dec. 31, 2025 7000 6.2 million 5.3 million -
Sept. 30, 2025 7000 5.4 million 3.9 million -4000

ATOS Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 - -
March 31, 2026 - 4000
Dec. 31, 2025 - 4000
Sept. 30, 2025 - 4000

ATOS

Price: $2.59

52 week price:
1.70
19.35

Earnings Per Share: -4.34 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 530800

Ebitda: -2.0 million

Market Capitalization: 25.9 million

Links: